A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)

Dev, Anouk (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Reference Number: HREC/52357/SVHM-2019-172768(v2)
NMA SSA Reference Number: SSA/52357/MonH-2019-179151(v1)
Monash Health Ref Number: RES-19-0000-482X

Status	Active
Effective start/end date	26/07/19 → 25/07/24

View all

View less

Keywords

clinical trial
phase 3 study
treatment efficacy
liver cancer